A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer

PURPOSE: Gemcitabine (GEM)-based chemotherapy has been used worldwide as the first-line treatment for advanced biliary tract cancer (BTC). However, no standard regimens have been established yet for patients with GEM-refractory BTC. A previous phase II trial of S-1 as a first-line treatment in patie...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Suzuki, Eiichiro, Ikeda, Masafumi, Okusaka, Takuji, Nakamori, Shoji, Ohkawa, Shinichi, Nagakawa, Tatsuya, Boku, Narikazu, Yanagimoto, Hiroaki, Sato, Tosiya, Furuse, Junji
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer-Verlag 2013
Gaiak:
Original Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3636435/
https://ncbi.nlm.nih.gov/pubmed/23525694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2106-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak